此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Plasma Exchange in Children With Severe Sepsis and Septic Shock (PE/Sepsis)

2026年8月21日 更新者:Hani Hamed Saad、Menoufia University

Therapeutic Plasma Exchange in Children With Severe Sepsis and Septic Shock: A Randomized Controlled Clinical Trial

The aim of the study will be to to evaluate whether therapeutic plasma exchange (TPE) reduces mortality in critically ill children with severe sepsis or septic shock compared to the standard care of sepsis alone.

The study population will be divided into two groups, the first group will receive standard sepsis management plus therapeutic plasma exchange and the second one will receive the standard sepsis management alone . Then we will assess the effect of TPE on : Severity of organ dysfunction (pSOFA score) , duration of vasopressor support , length of PICU stay, time to hemodynamic stabilization , and on inflammatory and coagulation biomarkers

研究概览

地位

招聘中

详细说明

This will be a Prospective, randomized, controlled, open- label, parallel-group, center clinical trial, which will be conducted on critically ill children with severe sepsis and septic shock, admitted into the Pediatric Intensive Care Unit (PICU) of Menoufia University Hospital from August 2026 to February 2027.

Eligible patients will be randomized using a computer-generated random sequence into:

  1. - Intervention Group (plasma exchange Arm): Standard sepsis management plus therapeutic plasma exchange.
  2. - Control Group (Standard care Arm): Standard sepsis management alone. Interventions

Standard Care (Both Groups):

  1. - Early antimicrobial therapy
  2. - Fluid resuscitation.
  3. - Vasopressor and inotropic support
  4. - Mechanical ventilation as indicated
  5. - Organ support according to PICU protocols Therapeutic Plasma Exchange (TPE) Protocol

    • Initiation: Within 24 hours of diagnosis.
    • Frequency: Once daily for 1-5 sessions (Connelly et al.,2023)
    • Plasma Volume: 1-1.5 plasma volumes per session.
    • Replacement Fluid: Fresh frozen plasma (FFP).
    • Anticoagulation: Citrate or heparin according to institutional protocol.
    • Monitoring: Continuous hemodynamic and laboratory monitoring (All adverse events related to TPE (hypotension, bleeding, electrolyte disturbances, allergic reactions) will be recorded and managed according to PICU protocols.

All patients will be subjected to:

  1. Demographic data will be collected from each participant, including age, sex, and weight, height, and body mass index.
  2. Clinical Assessment:

    • Detailed history and physical examination.
    • Scoring of the severity of the disease using pSOFA (Pediatric Sequential Organ Failure Assessment) and PELOD-2 (Pediatric Logistic Organ Dysfunction 2) scores.
  3. Laboratory investigations:

1) - Complete blood count (CBC). 2) - C-reactive protein (CRP). 3) - Procalcitonin (PCT). 4) - Coagulation profile (PT, aPTT and INR). 5) - Liver functions (ALT and AST). 6) - Kidney functions (Urea and creatinine). 7) - Electrolytes: Sodium (Na), potassium (K) and Calcium (Ca) levels. 8) - Serum lactate level and LDH. 9) - Blood cultures for all cases, urine and CSF culture (if indicated).

研究类型

介入性

注册 (估计的)

22

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

  • 姓名:Nagwan Yossery Saleh, MD, pediatrics
  • 电话号码:+201003961071
  • 邮箱:drnagwan80@gmail.com

学习地点

    • Menoufia Governorate
      • Shibīn al Kawm、Menoufia Governorate、埃及
        • 招聘中
        • Menoufia university hospital, Pediatric intensive care unit
        • 接触:
        • 接触:
        • 首席研究员:
          • Hani Hamed Saad, MD, pediatrics
        • 副研究员:
          • Nagwan Yossery Saleh, MD, pediatrics
        • 副研究员:
          • Amira Zaki Badawy, MD, clinical pathology

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 孩子
  • 成人

接受健康志愿者

不

描述

Inclusion Criteria:

  1. From one month to 18 years.
  2. With an established diagnosis of severe sepsis or septic shock according to international pediatric sepsis definitions.

Exclusion Criteria:

  1. Known congenital bleeding disorders and severe uncontrolled hemorrhage.
  2. End-stage chronic illness with expected survival < 3 months.
  3. Previous plasma exchange during the same admission.
  4. Contraindications to central venous catheterization.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
有源比较器:Intervention Group (plasma exchange Arm)
this arm will receive standard sepsis management plus therapeutic plasma exchange.
Therapeutic plasma exchange to the intervention Group (plasma exchange Arm) that will receive also the standard sepsis management.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Primary Outcome Measure
大体时间:28 days
All-cause mortality within 28 days after randomization, defined as the proportion of participants who die from any cause within 28 days of enrollment.
28 days

次要结果测量

结果测量
措施说明
大体时间
Change in pediatric Sequential Organ Failure Assessment (pSOFA) score
大体时间:Baseline, Day 1, Day 3, and Day 7
Change in pSOFA score from baseline measured on days 1, 3, and 7 after randomization.
Baseline, Day 1, Day 3, and Day 7
Duration of vasopressor support
大体时间:Up to 28 days
Number of days participants require vasopressor support after randomization.
Up to 28 days
Length of pediatric intensive care unit (PICU) stay
大体时间:Up to 28 days
Number of days participants remain admitted to the PICU.
Up to 28 days
Time to shock resolution
大体时间:Up to 28 days
Time from randomization until resolution of septic shock
Up to 28 days
Change in C-reactive protein (CRP)
大体时间:Baseline, Day 3, and Day 7
Change in serum CRP concentration from baseline.
Baseline, Day 3, and Day 7
Change in procalcitonin concentration
大体时间:Baseline, Day 3, and Day 7
Change in serum procalcitonin concentration from baseline.
Baseline, Day 3, and Day 7
Platelet count
大体时间:Baseline, Day 3, and Day 7
Change in platelet count from baseline.
Baseline, Day 3, and Day 7
International normalized ratio (INR)
大体时间:Baseline, Day 3, and Day 7
Change in INR from baseline.
Baseline, Day 3, and Day 7
Fibrinogen concentration
大体时间:Baseline, Day 3, and Day 7
Change in plasma fibrinogen concentration from baseline.
Baseline, Day 3, and Day 7
Incidence of therapeutic plasma exchange-related adverse events
大体时间:Up to 28 days
Number of participants experiencing adverse events related to therapeutic plasma exchange.
Up to 28 days

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Hani Hamed Saad, MD, pediatrics、Faculty of medicine, Menoufia University

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年8月1日

初级完成 (估计的)

2027年2月28日

研究完成 (估计的)

2027年3月31日

研究注册日期

首次提交

2026年7月2日

首先提交符合 QC 标准的

2026年7月13日

首次发布 (实际的)

2026年7月15日

研究记录更新

最后更新发布 (实际的)

2026年8月24日

上次提交的符合 QC 标准的更新

2026年8月21日

最后验证

2026年7月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅